8279 Share Price Performance
Recent 8279 News & Updates
No updates
Syngen Biotech Co.,Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 10.31
- Gross Margin
- 36.27%
- Net Profit Margin
- 13.16%
- Debt/Equity Ratio
- 4.2%
Syngen Biotech Co.,Ltd. Competitors
About 8279
- Founded
- 1988
- Employees
- n/a
- CEO
- WebsiteView website
Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan, China, and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies; science-based and bio active pharmaceutical ingredients under the Oraltics, IMMUPHYLA, V3, ST4SanTex, GUARDSPO, benefiGANO, EXPUNERGY, and BIOJOVIAL brands; and private labelling services. It also provides organic food OEM/ODM, explosion proof extraction, brand agency, and wholesale distribution services. The company serves the sport nutrition, beauty enhancement, baby and mother care, weight management, and digestion and detox industries. It exports to approximately 20 countries. Syngen Biotech Co.,Ltd. was founded in 1988 and is based in Tainan City, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.6%
- 3 Months: 12.7%
- 1 Year: 2.4%
- Year to Date: 2.3%
Over the last 7 days, the market has remained flat, although notably the Energy sector gained 9.2% in that time. Similarly, the market is flat for the past 12 months. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading